15 To 23 Amino Acid Residues In Defined Sequence Patents (Class 530/326)
-
Publication number: 20130315902Abstract: Described herein is novel isolated or synthetic peptides derived from a complementarity determining region hypervariable domain amino acid sequence of a humanized monoclonal antibody to NaPi2B transporter, as well as derivatives thereof, and a pharmaceutical composition and a method for inhibiting tumor growth or treating a tumor or cancer treating using the antitumor peptides and derivatives thereof.Type: ApplicationFiled: December 14, 2011Publication date: November 28, 2013Applicant: RECEPTA BIOPHARMA S.A.Inventor: Luiz Rodolpho Raja Gabaglia Travassos
-
Publication number: 20130318648Abstract: A method of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising: (a) contacting a sample from the host with an agent selected from (i) the epitope comprising sequence which is: SEQ ID NO: 1 or 2, or an equivalent sequence from a naturally occurring homologue of the gliadin represented by SEQ ID NO: 3, (ii) an epitope comprising sequence comprising: SEQ ID NO: 1, or an equivalent sequence from a naturally occurring homologue of the gliadin represented by SEQ ID NO: 3, which epitope is an isolated oligopeptide derived from a gliadin protein, (iii) an analogue of (i) or (ii) which is capable of being recognised by a T cell receptor that recognises (i) or (ii), which in the case of a peptide analogue is not more than 50 amino acids in length, or (iv) a product comprising two or more agents as defined in (i), (ii) or (iii), and (b) determining in vitro whether T cells in the sample recognise the agent; recognition by the T cells indicating that the individual has, or is suType: ApplicationFiled: November 8, 2012Publication date: November 28, 2013Applicant: ISIS INNOVATION LIMITEDInventors: ROBERT PAUL ANDERSON, ADRIAN VIVIAN HILL, DEREK PARRY JEWELL
-
Publication number: 20130315984Abstract: The present invention provides methods of killing, inhibiting the growth, and/or inhibiting the reproduction of kinetoplastid protozoan with hydrophobic signal sequence peptides and compositions including such hydrophobic signal sequence peptides.Type: ApplicationFiled: May 31, 2013Publication date: November 28, 2013Applicant: University of Georgia Studies Research CenterInventor: University of Georgia Studies Research Center
-
Publication number: 20130316448Abstract: The present invention relates to certain biologically active peptides and polypeptides which can be used as therapeutics or prophylactics against diseases or disorders linked to NGF as the causative agent. In one aspect of the present invention, pharmacologically active polypeptides comprising peptides linked to one or more Fc domains are provided.Type: ApplicationFiled: August 2, 2013Publication date: November 28, 2013Applicant: AMGEN INC.Inventors: Thomas C. Boone, Kenneth D. Wild, Karen C. Sitney, Ho-Sung Min, Bruce Kimmel
-
Patent number: 8591907Abstract: The invention provides hypoallergenic variants of Bet v 2 major allergen from Betula verrucosa plant pollen and the use thereof for the preventive or therapeutic treatment of allergic diseases.Type: GrantFiled: September 16, 2008Date of Patent: November 26, 2013Assignee: Lofarma S.p.A.Inventors: Giovanni Mistrello, Stefania Zanotta, Daniela Roncarolo, Paolo Falagiani
-
Publication number: 20130310313Abstract: A polypeptide, a nucleic acid molecule encoding the polypeptide and a pharmaceutical composition comprising the polypeptide are provided. The polypeptide is as defined in the description, can bind to insulin receptors, and is effective in reducing blood sugar, reducing glycated hemoglobin, and ameliorating hepato-renal disorders caused by diabetes.Type: ApplicationFiled: July 25, 2012Publication date: November 21, 2013Inventors: Tin-Yun HO, Chien-Yun HSIANG
-
Publication number: 20130310306Abstract: The present invention relates to new peptides and to use thereof, in particular for treatment and/or prevention of infections, inflammations, pain, wounds, scar and/or tumours.Type: ApplicationFiled: January 25, 2012Publication date: November 21, 2013Applicant: PharmaSurgics In Sweden ABInventors: Margit Mahlapuu, Camilla Bjöm, Veronika Sjöstrand, Bjöm Walse, Bo Svenson
-
Publication number: 20130309179Abstract: The present invention relates to an oral composition and an immunogenic composition for the suppression of the pathogenic effects of the intra-oral bacterium Porphyromonas gingivalis associated with periodontal disease.Type: ApplicationFiled: March 28, 2013Publication date: November 21, 2013Applicant: The University of MelbourneInventors: Eric Charles Reynolds, Neil Martin O'BRIEN-SIMPSON, Nada SLAKESKI
-
Publication number: 20130309222Abstract: We have disclosed affinity peptides toward infliximab. More specifically we have disclosed an affinity biomatrix where the affinity peptide is covalently attached to a biocompatible, biodegradable polymer. The affinity biomatrix is useful in preparing controlled release devices for infliximab.Type: ApplicationFiled: May 17, 2012Publication date: November 21, 2013Applicant: Advanced Technologies and Regenerative Medicine, LLCInventors: Daphne Ann Salick Ryan, John Kehoe, John Wheeler, Chunlin Yang, Abla Creasey
-
Patent number: 8586544Abstract: The present invention relates to a cell-permeable endostatin recombinant protein in which a macromolecule transduction domain (MTD) is fused to an angiogenesis inhibitor (angiogenesis inhibitor) endostatin; a polynucleotide encoding the cell-permeable endostatin recombinant protein; an expression vector for the cell-permeable endostatin recombinant protein; and a pharmacological composition for an anti-cancer preparation with improved inhibitory activity against angiogenesis in cancer, which contains the cell-permeable endostatin recombinant protein as an active component.Type: GrantFiled: April 3, 2009Date of Patent: November 19, 2013Assignees: Procell Therapeutics Inc.Inventors: Daewoong Jo, Jong Min Lee, Kyoungho Park, Minh Tam Duong
-
Publication number: 20130303439Abstract: The invention related to chimeric peptides including a penetrating peptide and a binding domain of PP2A catalytic subunit to caspase-9 which have pro-apoptotic activity. These chimeric peptides may be used for the treatment of hyperproliferative disorders.Type: ApplicationFiled: September 30, 2011Publication date: November 14, 2013Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), INSTITUT CURIEInventors: Angelita Rebollo Garcia, Didier Decaudin, Fariba Nemati
-
Publication number: 20130302249Abstract: Peptide ligands for transporting therapeutic agents across the intestinal epithelial barrier that ordinarily are inadequately absorbed and must be delivered by alternative means, which contain an isolated amino acid sequence wherein at least one pair of amino acids are of an opposite charge and the pair members are separated by a spacer of 1-12 amino acid residues including at least one hydrophobic amino acid, and wherein the length of the amino acid sequence is greater than 5 and less than 20 amino acids. Pharmaceutical compositions for gastro-intestinal delivery and methods for the gastrointestinal delivery of poorly absorbed therapeutic agents are also disclosed.Type: ApplicationFiled: October 14, 2011Publication date: November 14, 2013Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Patrick J. Sinko, Xiaoping Zhang, Zoltan Szekely
-
Publication number: 20130303449Abstract: The present invention relates to the clinical application of BBP, alone or in combination with other growth factors, for use in bone healing applications, such as spinal surgery. Additional applications include use in orthopedic implantable prostheses and implantation into other surgical sites (e.g., surgical reconstruction, regional osteopenia, etc.) where bone is desired.Type: ApplicationFiled: April 5, 2013Publication date: November 14, 2013Inventors: Samuel S. MURRAY, Elsa J. BROCHMANN-MURRAY, Keyvan BEHNAM, Jeffrey C. WANG
-
Publication number: 20130302364Abstract: The invention relates to peptides comprising part or all of a conserved element within a Center-of-Tree (COT) sequence derived from a family of polypeptides encoded by naturally occurring variants of HIV. The invention also relates to immunogenic compositions and vaccines comprising said peptides. The invention also relates to methods for the identification of HIV controller patients based on the detection of the T cells of the patient to mount a cytotoxic T cell response against said peptides and to methods for the identification of immunogenic peptides within a family of variant polypeptides.Type: ApplicationFiled: November 10, 2011Publication date: November 14, 2013Applicants: LABORATORIOS DEL DR. ESTEVE, S.A., UNIVERSITY OF WASHINGTON, INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS, FUNDACIÓ PRIVADA INSTITUT DE RECERCA DE LA SIDA - CAIXAInventors: Beatriz Mothe Pujadas, Christian Brander, James I. Mullins
-
Publication number: 20130302334Abstract: Specific peptides, and derived ionization characteristics of those peptides, from the Bcl-2-like protein 11 (BIM) are provided that are particularly advantageous for quantifying the BIM protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM). Such biological samples are chemically preserved and fixed where the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.Type: ApplicationFiled: July 15, 2013Publication date: November 14, 2013Applicant: EXPRESSION PATHOLOGY, INC.Inventors: David Krizman, Todd Hembrough, Sheeno Thyparambil, Wei-Li Liao
-
Patent number: 8580746Abstract: Cyclic constructs which bind to a natriuretic peptide receptor and include a plurality of amino acid residues, at least one amino acid surrogate of formula I: where R, R?, Q, Y, W, Z, J, x and n are as defined in the specification, and a cyclic linkage including one or two amide bonds, pharmaceutical compositions including such cyclic constructs, and methods of treating congestive heart failure or other conditions, syndromes or diseases for which induction of anti-hypertensive, cardiovascular, renal or endocrine effects are desired.Type: GrantFiled: October 2, 2009Date of Patent: November 12, 2013Assignee: Palatin Technologies, Inc.Inventors: Shubh D. Sharma, Margarita Bastos, Wei Yang
-
Patent number: 8580922Abstract: Disclosed herein are novel peptide linkers and polypeptide compositions comprising the linkers (e.g., chimeric polypeptides) and methods of using the polypeptide compositions. The compositions and methods are particularly useful for targeting/delivering a polypeptide or protein of interest (e.g., a therapeutic polypeptide) to a cell, tissue or organ of interest in order to treat various diseases or disorders (e.g., lysosomal storage disorders).Type: GrantFiled: March 2, 2012Date of Patent: November 12, 2013Assignee: Shire Human Genetic Therapies, Inc.Inventors: Paolo Martini, Michael Concino
-
Patent number: 8580923Abstract: Amphiphilic peptide compounds comprising one or more epitope sequences for binding interaction with one or more corresponding growth factors, micellar assemblies of such compounds and related methods of use.Type: GrantFiled: March 19, 2012Date of Patent: November 12, 2013Assignee: Northwestern UniversityInventors: Samuel I. Stupp, Jack J. J. M. Donners, Gabriel A. Silva, Heather A. Behanna, Shawn G. Anthony
-
Patent number: 8580269Abstract: Compositions and methods for stimulating an immune response against cells that express survivin are provided. The method is suitable for prophylaxis and/or therapy of autoimmune disorders. The method involves administering to an individual a composition that contains a survivin peptide mimic that has a cysteine to methionine alteration at amino acid position 57 of wild type survivin. Fragments of the peptides can also be used.Type: GrantFiled: May 4, 2011Date of Patent: November 12, 2013Assignee: Health Research, Inc.Inventors: Michael J. Ciesielski, Robert A. Fenstermaker
-
Publication number: 20130295106Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and other polypeptides, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided. Screening methods are also provided.Type: ApplicationFiled: March 13, 2013Publication date: November 7, 2013Inventors: Austin L. Gurney, Aaron Ken Sato, Fumiko Takada Axelrod, Timothy Charles Hoey, Sanjeev H. Satyal, Satyajit Sujit Kumar Mitra
-
Patent number: 8575306Abstract: Target and method for inhibition of bacterial RNA polymerase disclosed are targets and methods for specific binding and inhibition of RNAP from bacterial species.Type: GrantFiled: May 29, 2012Date of Patent: November 5, 2013Assignee: Rutgers, The State University of New JerseyInventor: Richard H. Ebright
-
Patent number: 8575103Abstract: Permeable Switch Region I and II peptides in the range of 9 to 25 amino acid residues in length are provided for specifically inhibiting signaling through G? subunits. In addition, compositions and methods for inhibiting platelet aggregation and ?11b?3 integrin activation using the Switch Region I and II peptides are provided.Type: GrantFiled: March 21, 2012Date of Patent: November 5, 2013Assignee: The Board of Trustees of the University of IllinoisInventors: Guy Le Breton, Jin-Sheng Huang, Subhashini Srinivasan, Fadi T. Khasawneh
-
Patent number: 8574660Abstract: Processes are described herein for preparing medical devices and other articles having a low-fouling surface on a substrate comprising a polymeric surface. The polymeric surface material may possess a range of polymeric backbones and substituents while providing the articles with a highly efficient, biocompatible, and non-fouling surface. The processes involve treating the substrate to reduce the concentration of chemical species on the surface of or in the substrate without altering the bulk physical properties of the device or article, and thereafter forming a grafted polymer layer on the treated substrate surface.Type: GrantFiled: June 9, 2011Date of Patent: November 5, 2013Assignee: Semprus Biosciences CorporationInventors: Douglas J. K. Weaver, Jun Li, Zheng Zhang, Abby N. Deleault, Eric W. Marchese, Phu C. Nguyen, Chad C. Huval, Michael A. Bouchard, Arthur J. Coury, Christopher R. Loose
-
Patent number: 8575107Abstract: Clusterin-derived peptides or homologues or derivatives thereof, pharmaceutical compositions including the same, methods of manufacturing the peptides, homologues, derivatives thereof and compositions including the same, and methods of treating conditions including administering the peptides, homologues, derivatives thereof and compositions including the same, are provided. Also provided are nucleotide sequences encoding the peptides, homologues, derivatives thereof and compositions including the same, antibodies directed to epitopes thereof and fusion proteins including the same.Type: GrantFiled: January 22, 2009Date of Patent: November 5, 2013Assignee: Compugen Ltd.Inventors: Yossef Kliger, Ofer Levy, Itamar Borukhov, Assaf Wool, Ehud Schreiber, Anat Amir, Zurit Levine, Zohar Tiran, Anat Oren, Amir Toporik
-
Patent number: 8575093Abstract: A method of preventing and/or treating S. pneumoniae infection in mammalian subjects, wherein said method comprises administering to said subjects a composition comprising one or more agents that are capable of inhibiting the binding of the S. pneumoniae cell wall protein FBA to the respiratory tract cells of said subject.Type: GrantFiled: September 29, 2008Date of Patent: November 5, 2013Assignees: Ben-Gurion University of the Negev Research and Development Authority, Mor Research Applications Ltd.Inventors: Yaffa Mizrachi Nebenzahl, Ron Dagan
-
Publication number: 20130287786Abstract: The present invention relates to the field of veterinary parasitology, especially of canine Babesiosis. In particular the invention relates to a polypeptide being a novel canine Babesia antigen (CBA), or fragments thereof, and to compositions comprising this antigen, to nucleic acids encoding the antigen, antibodies against the antigen, and medical uses of this antigen, fragments, antibodies, or encoding nucleic acids. In particular the invention relates to the use of such components in vaccines against canine Babesiosis.Type: ApplicationFiled: December 28, 2011Publication date: October 31, 2013Inventors: Theodorus Petrus Maria Schetters, Karina Moubri-Menage, Jose Kleuskens, Andreas Walter Claudius Rohwer
-
Publication number: 20130289237Abstract: An isolated antibody specifically binding the C-terminus part of the MCM9 protein, the C-terminus part of the MCM9 protein is one of the following sequences: the amino acids sequence from the position 391 to the position 1143 of the MCM9 proteins of the sequence as set forth in SEQ ID NO: 2 or 16, or the amino acids sequence from the position 391 to the position 1143 of the MCM9 protein of the sequence as set forth in SEQ ID NO: 8.Type: ApplicationFiled: June 26, 2013Publication date: October 31, 2013Inventors: MARCEL MECHALI, DOMENICO MAIORANO, MALIK LUTZMANN
-
Publication number: 20130288965Abstract: The current invention relates to the use of a peptide comprising an amino acid sequence in the preparation of a medicament for the regeneration of tissue, preferably for the treatment of a wound. Further the invention relates to compositions comprising such peptides, and use of said peptides in both medical and nonmedical (cosmetic) applications.Type: ApplicationFiled: March 14, 2013Publication date: October 31, 2013Inventors: JOHANNES GERHARDUS MARIA BOLSCHER, ARIE VAN NIEUW AMERONGEN, ENGELMUNDUS CORNELIS IGNATIUS VEERMAN, MENNO JOHANNES OUDHOFF, WILLEM VAN'T HOF, KAMRAN NAZMI, PETRONELLA ADRIANA MARIA VAN DEN KEIJBUS
-
Publication number: 20130289142Abstract: The current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the Receptor Tyrosine-Protein Kinase erbB-3, or Her3, that are particularly advantageous for quantifying the Her3 protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein said biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.Type: ApplicationFiled: July 1, 2013Publication date: October 31, 2013Applicant: EXPRESSION PATHOLOGY, INC.Inventors: David Krizman, Todd Hembrough, Sheeno Thyparambil
-
Publication number: 20130288980Abstract: The present invention relates to agents that inhibit FOXO4 function and uses thereof in treating cancer and/or removing senescent cells in an individual.Type: ApplicationFiled: March 14, 2013Publication date: October 31, 2013Inventors: Peterus Leonardus-Josephus De Keizer, Judith Campisi, Remi-Martin Laberge
-
Publication number: 20130288979Abstract: The invention relates to fragments of the DAXX and FADD proteins that inhibit cell apoptosis, in particular cell apoptosis mediated by the Fas receptor. The invention also relates to derivatives of said anti-apoptotic fragments, conjugates comprising said fragments, pharmaceutical compositions comprising said fragments, and to the medical applications of said fragments, derivatives, conjugates, and pharmaceutical compositions thereof in the treatment or prevention of diseases and conditions associated with apoptosis.Type: ApplicationFiled: November 17, 2011Publication date: October 31, 2013Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS, UNIVERSITE DE MONTPELLIER 1, UNIVERSITE MONTPELLIER 2-SCIENCES ET TECHNIQUEInventors: Stéphanie Barrere, Joël Nargeot, Bernard Lebleu, Prisca Boisguerin, Christophe Piot
-
Publication number: 20130288948Abstract: A motif is searched which can inhibit the proteolysis of a protein that has been administered to a cell or an individual. Thus, disclosed is a method for designing/producing a protein having resistance to proteolysis. Specifically disclosed is a motif capable of inhibiting proteolysis, which comprises an amino acid region lying between the 396th position and the 410th position from the C-terminal of DP-1.Type: ApplicationFiled: November 20, 2009Publication date: October 31, 2013Applicant: NIHON UNIVERSITYInventors: Shigemasa Hanazawa, Yoshikazu Masuhiro
-
Patent number: 8569005Abstract: In accordance with certain embodiments of the present disclosure, a protein arginine methyltransferase inhibitor is provided. The inhibitor comprises an amino acid peptide joined to a chloroacetamidine warhead.Type: GrantFiled: November 7, 2012Date of Patent: October 29, 2013Assignee: University of South CarolinaInventors: Paul R. Thompson, Tanesha C. Osborne, Obiamaka Obianyo, Corey P. Causey
-
Patent number: 8569448Abstract: Provided are methods for detecting various subunits and isoforms of NMDA receptors to help diagnose and differentiate (1) the anatomical location of NMDA receptor over-expression. (2) ischemic conditions in the central and peripheral nervous systems, and (3) the type and cause of chronic pain.Type: GrantFiled: July 25, 2011Date of Patent: October 29, 2013Assignee: Grace Laboratories, LLCInventor: Svetlana A. Dambinova
-
Patent number: 8569244Abstract: An objective of the present invention is to provide a means for enabling cancer immunotherapy that targets approximately 30% of various cancer patients that highly express forkhead box M1 (FOXM1) among the Japanese, by identifying FOXM1-derived peptides that can activate cancer cell-damaging human killer T cells by binding to HLA-A2. The present invention provides a peptide of (A) or (B) below: (A) a peptide including the amino acid sequence of any one of SEQ ID NOs: 1 to 3; (B) a peptide which includes the amino acid sequence of any one of SEQ ID NOs: 1 to 3, wherein one, two, or several amino acid(s) are substituted, deleted, inserted, and/or added, and wherein the peptide shows cytotoxic (killer) T cell-inducing activity.Type: GrantFiled: August 12, 2008Date of Patent: October 29, 2013Assignee: OncoTherapy Science, Inc.Inventors: Yasuharu Nishimura, Kazunori Yokomine, Takuya Tsunoda, Yusuke Nakamura
-
Patent number: 8569246Abstract: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition including Crohn's disease and ulcerative colitis, and cancer.Type: GrantFiled: December 31, 2012Date of Patent: October 29, 2013Assignee: Synergy Pharamaceuticals Inc.Inventor: Kunwar Shailubhai
-
Patent number: 8569230Abstract: The present invention provides novel kinocidin peptides comprising a C-terminal portion of a kinocidin, wherein the C-terminal portion encompasses an ?-helical secondary structure and further displays antimicrobial activity. The kinocidin peptides of the invention are derived from and correspond to a C-terminal portion of a kinocidin that includes a ?KC core and that can be a CXC, CC, or C class chemokine. Structural, physicochemical and functional properties of this novel class of antimicrobial peptides and amino acid sequences of particular kinocidin peptides are also disclosed. The invention also provides related antimicrobial methods.Type: GrantFiled: May 5, 2011Date of Patent: October 29, 2013Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventors: Nannette I. Yount, Michael Yeaman
-
Patent number: 8569447Abstract: The invention provides cell-permeable peptides that bind to JNK proteins and inhibit JNK-mediated effects in JNK-expressing cells.Type: GrantFiled: July 20, 2012Date of Patent: October 29, 2013Assignee: Xigen SAInventor: Christophe Bonny
-
Patent number: 8569449Abstract: The present invention provides Parotid Secretory Protein peptides, nucleic acids encoding the peptides, and methods of using the peptides, and methods of screening GL13 mimetics.Type: GrantFiled: May 8, 2008Date of Patent: October 29, 2013Assignee: University of Louisville Research Foundation, Inc.Inventor: Sven-Ulrik Gorr
-
Publication number: 20130280281Abstract: The present invention relates to short polypeptides (e.g., fewer than 19 amino acids in length) and longer polypeptides (e.g., 19 or more amino acids in length) having one or more D-amino acids as targeting moieties. These polypeptides, when conjugated to agents (e.g., therapeutic agents or transport vectors) are capable of transporting the agents across the BBB or into particular cell types. In particular, the short polypeptides can include one or more D-amino acids. These compounds are therefore particularly useful in the treatment of neurological diseases or diseases associated with particular cell types, organs, or tissues.Type: ApplicationFiled: July 4, 2011Publication date: October 24, 2013Inventors: Jean-Paul Castaigne, Michel Demeule, Christian Che, Carine Thiot, Laurence Peslherbe
-
Publication number: 20130281309Abstract: The present invention aims to present methods to detect nonalcoholic fatty liver disease including nonalcoholic steatohepatitis by using a protein or its partial peptide that differs in presence or absence, or in quantity between healthy human subjects and patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis or between patients with fatty liver and nonalcoholic steatohepatitis and further aims to present biomarkers comprising said protein and said partial peptide to be used to detect nonalcoholic fatty liver disease including nonalcoholic steatohepatitis. Specifically, 35 kDa protein fragment consisting of amino acid sequence expressed by Sequence No. 2 and its partial peptide consisting of amino acid sequence expressed by Sequence No. 3 (including its glycated form) of inter-alpha-trypsin inhibitor heavy chain H4 precursor consisting of amino acid sequence expressed by Sequence No.Type: ApplicationFiled: September 16, 2009Publication date: October 24, 2013Inventors: Kohji Meno, Hideaki Suzuki
-
Patent number: 8563508Abstract: The invention describes peptide analogues of ?-melanocyte-stimulating hormone (?-MSH), which possess an increased efficacy compared to the native ?-MSH peptide. The ?-MSH analogues exhibit increased anti-inflammatory effects and increased capability to prevent ischemic conditions compared to ?-MSH. The invention further discloses use of the peptides for the manufacture of pharmaceutical compositions for the treatment or prophylaxis of a condition in the tissue of one or more organs of a mammal, and moreover pharmaceutical compositions.Type: GrantFiled: March 19, 2013Date of Patent: October 22, 2013Assignee: AbbVie Inc.Inventors: Thomas E. N. Jonassen, Soren Nielsen, Jorgen Frokiaer, Bjarne Due Larsen
-
Patent number: 8563688Abstract: A peptide or peptide derivative comprising: (i) WDLYFEIVW (SEQ ID NO: 1); or (ii) a variant amino acid sequence comprising one, two, three or four L-amino acid substitutions in WDLYFEIVW (SEQ ID NO: 1); or (iii) the retro-inverso variant of the peptide or peptide derivative of either one of parts (i) and (ii), wherein said peptide or peptide derivative has procoagulant activity. A peptide or peptide derivative comprising: (i) an amino acid sequence comprising imfwydcye; or (ii) a variant amino acid sequence comprising one, two, three, four, five or six amino acid substitutions in imfwydcye, wherein said peptide or peptide derivative has procoagulant activity.Type: GrantFiled: April 16, 2009Date of Patent: October 22, 2013Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Friedrich Scheiflinger, Michael Dockal
-
Patent number: 8563689Abstract: The present invention includes methods of modulating cellular secretory processes. More specifically the present invention relates to modulating or reducing the release of inflammatory mediators from inflammatory cells by inhibiting the mechanism associated with the release of inflammatory mediators from the vesicles or granules in the inflammatory cells in a subject with a chronic inflammatory disease. In this regard, the present invention discloses an intracellular signaling mechanism that illustrates several novel intracellular targets for pharmacological intervention in disorders involving secretion of inflammatory mediators from vesicles in inflammatory cells. MANS peptide and active fragments thereof are useful in such methods.Type: GrantFiled: June 4, 2009Date of Patent: October 22, 2013Assignees: North Carolina State University, Biomarck Pharmaceuticals, Ltd.Inventors: Shuji Takashi, Indu Parikh, Kenneth B. Adler, Linda D. Martin, Yuehua Li
-
Patent number: 8563514Abstract: Provided is a pharmaceutical composition for sequestering cells in connective tissue. The composition includes a biocompatible scaffolding to which one or more peptides or proteins are linked. The peptides or proteins have an amino acid sequence that is a subsequence of human ficolin and are capable of binding the cells to be sequestered. The pharmaceutical composition can be used in the treatment of connective tissue, and can be used as a dermal filler.Type: GrantFiled: August 14, 2008Date of Patent: October 22, 2013Assignee: MetamorefixInventors: Mazal Dahan, Raphael Gorodetsky
-
Patent number: 8563683Abstract: The present invention relates to synthetic lung surfactant compositions that contain one or more of phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, and surface active proteins or peptides, more preferably a combination of at least two or all three of these materials. Novel phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, and surface active peptides are also disclosed herein. Uses of the surfactant compositions of the present invention to treat endogenous surfactant dysfunctional or deficient lung tissue, to prepare synthetic peptides for use in the surfactant compositions, and to deliver therapeutic agents are also disclosed.Type: GrantFiled: July 20, 2007Date of Patent: October 22, 2013Assignees: University of Rochester, The Los Angeles BioMedical Research Institute at Harbor—UCLA Medical Center, University of GuelphInventors: Robert H. Notter, Zhengdong Wang, Adrian L. Schwan, Zhongyi Wang, Jason A. Davy, Alan J. Waring, Frans J. Walther, Larry M. Gordon
-
Publication number: 20130274200Abstract: It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.Type: ApplicationFiled: April 5, 2013Publication date: October 17, 2013Inventors: Koji Kawakami, Masayuki Kohno, Tomohisa Horibe, Oumi Nakajima, Mari Haramoto, Liying Yang
-
Publication number: 20130273647Abstract: The present invention relates to efficient methods for providing antigen-specific lymphoid cells. These lymphoid cells may be used to provide antigen specific T cell receptors having a defined MHC restriction and to identify immunologically relevant T cell epitopes. Furthermore, the present invention relates to antigen-specific T cell receptors and T cell epitopes and their use in immunotherapy.Type: ApplicationFiled: September 19, 2011Publication date: October 17, 2013Applicants: BIONTECH AG, TRON- Translationale Onkologie an der Universi- ttttatsmedzin der Johannes Gutenberg- UNiversitat, Universitatsmedizin der Johannes Gutterberg- Universital MAinzInventors: Ugur Sahin, Ozlem Tureci, Petra Simon, Tana Omokoko
-
Publication number: 20130274202Abstract: The present invention relates to peptide from 4 to 50 amino acids comprising a phosphorylated pYX1X2X1 motif (SEQ ID NO: 1), wherein each X1 independently is M or Nle and X2 is any amino acid, pharmaceutical compositions comprising said peptide and use thereof for treating cancer.Type: ApplicationFiled: December 12, 2011Publication date: October 17, 2013Applicant: GENE SIGNAL INTERNATIONAL SAInventors: Salman Al-Mahmood, Sylvie Colin
-
Publication number: 20130274193Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.Type: ApplicationFiled: March 14, 2013Publication date: October 17, 2013Applicants: BAXTER HEALTHCARE SA, BAXTER INTERNATIONAL INC.Inventors: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE SA